Novartis’ Ilaris (canakinumab) Fails to Meet its Primary Endpoints in P-lll Study for COVID-19 Pneumonia and CRS

November 9, 2020 Auto Bot Clinical Trials, Novartis, P-lll, Report, results 0

Shots:

  • The P-lll CAN-COVID trial involves assessing Ilaris (canakinumab) + SOC vs PBO + SoC in 454 patients aged 18-98yrs. with COVID-19 pneumonia and cytokine release syndrome CRS, with its expected full results in early 2021
  • Result: The trial fails to meet its 1EPs of survival without the need for mechanical ventilation up to day29 (88.8% vs 85.7%) and did not meet its 2EPs of COVID-19-related mortality up to 4 wks. (4.9% vs 7.2%)
  • Canakinumab is mAb that binds to and neutralizes (IL-1β), blocking its action. Additionally, P-III trial for ruxolitinib in COVID-19 is ongoing, with preliminary results expected by end of 2020

Click here ­to­ read full press release/ article | Ref: Novartis | Image: US News Health

The post Novartis’ Ilaris (canakinumab) Fails to Meet its Primary Endpoints in P-lll Study for COVID-19 Pneumonia and CRS first appeared on PharmaShots.